We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Iovance Biotherapeutics (IOVA - Free Report) . Shares have lost about 2.1% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Iovance Biotherapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Q4 Earnings & Sales Beat Estimates
Iovance incurred a fourth-quarter 2025 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 22 cents. In the year-ago quarter, the company reported a loss per share of 26 cents.
Total revenues for the fourth quarter rose 17.6% year over year to $87 million, generated entirely from the sales of the company’s two marketed drugs. The top line beat the Zacks Consensus Estimate of $75 million.
Quarter in Detail
IOVA recorded approximately $65 million from Amtagvi sales during the quarter, representing a 33.4% year-over-year increase, driven by robust demand. This figure beat the Zacks Consensus Estimate of $61 million.
Proleukin generated $22 million during the quarter, down 12% year over year. The figure beat the Zacks Consensus Estimate of $15 million.
Research & development expenses totaled $71.2 million in the fourth quarter, up 0.3% from the year-ago period.
Selling, general and administrative expenses declined 14% from the prior-year quarter’s figure to $36.4 million, mainly due to lower stock compensation expenses.
As a result of a restructuring plan initiated in August 2025, Iovance has started experiencing the benefits of cost optimization. The company reported a gross margin of 50% in the fourth quarter compared with 43% in the previous quarter, driven by improved operational efficiency.
Full-Year 2025 Results
For 2025, Iovance reported total revenues of approximately $264 million, representing a 61% year-over-year increase. Revenues were within the guidance range of $250 million to $300 million in the first full year of Amtagvi’s launch.
The company recorded a net loss per share of $1.09, narrower than a loss of $1.28 per share in 2024.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
The consensus estimate has shifted 22.73% due to these changes.
VGM Scores
At this time, Iovance Biotherapeutics has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Iovance Biotherapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Iovance Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Amicus Therapeutics (FOLD - Free Report) , a stock from the same industry, has gained 0.6%. The company reported its results for the quarter ended December 2025 more than a month ago.
Amicus Therapeutics reported revenues of $185.21 million in the last reported quarter, representing a year-over-year change of +23.7%. EPS of $0.10 for the same period compares with $0.09 a year ago.
For the current quarter, Amicus Therapeutics is expected to post earnings of $0.12 per share, indicating a change of +300% from the year-ago quarter. The Zacks Consensus Estimate has changed +7.7% over the last 30 days.
Amicus Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Iovance Biotherapeutics (IOVA - Free Report) . Shares have lost about 2.1% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Iovance Biotherapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Q4 Earnings & Sales Beat Estimates
Iovance incurred a fourth-quarter 2025 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 22 cents. In the year-ago quarter, the company reported a loss per share of 26 cents.
Total revenues for the fourth quarter rose 17.6% year over year to $87 million, generated entirely from the sales of the company’s two marketed drugs. The top line beat the Zacks Consensus Estimate of $75 million.
Quarter in Detail
IOVA recorded approximately $65 million from Amtagvi sales during the quarter, representing a 33.4% year-over-year increase, driven by robust demand. This figure beat the Zacks Consensus Estimate of $61 million.
Proleukin generated $22 million during the quarter, down 12% year over year. The figure beat the Zacks Consensus Estimate of $15 million.
Research & development expenses totaled $71.2 million in the fourth quarter, up 0.3% from the year-ago period.
Selling, general and administrative expenses declined 14% from the prior-year quarter’s figure to $36.4 million, mainly due to lower stock compensation expenses.
As a result of a restructuring plan initiated in August 2025, Iovance has started experiencing the benefits of cost optimization. The company reported a gross margin of 50% in the fourth quarter compared with 43% in the previous quarter, driven by improved operational efficiency.
Full-Year 2025 Results
For 2025, Iovance reported total revenues of approximately $264 million, representing a 61% year-over-year increase. Revenues were within the guidance range of $250 million to $300 million in the first full year of Amtagvi’s launch.
The company recorded a net loss per share of $1.09, narrower than a loss of $1.28 per share in 2024.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
The consensus estimate has shifted 22.73% due to these changes.
VGM Scores
At this time, Iovance Biotherapeutics has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Iovance Biotherapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Iovance Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Amicus Therapeutics (FOLD - Free Report) , a stock from the same industry, has gained 0.6%. The company reported its results for the quarter ended December 2025 more than a month ago.
Amicus Therapeutics reported revenues of $185.21 million in the last reported quarter, representing a year-over-year change of +23.7%. EPS of $0.10 for the same period compares with $0.09 a year ago.
For the current quarter, Amicus Therapeutics is expected to post earnings of $0.12 per share, indicating a change of +300% from the year-ago quarter. The Zacks Consensus Estimate has changed +7.7% over the last 30 days.
Amicus Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.